KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Liabilities and Shareholders Equity (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Liabilities and Shareholders Equity for 17 consecutive years, with $10.6 billion as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 12.95% to $10.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $30.5 billion, a 200.2% increase, with the full-year FY2025 number at $10.6 billion, up 12.95% from a year prior.
  • Liabilities and Shareholders Equity was $10.6 billion for Q4 2025 at Bio-Rad Laboratories, up from $9.7 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $20.0 billion in Q3 2021 to a low of $287.1 million in Q4 2023.
  • A 5-year average of $9.9 billion and a median of $11.9 billion in 2023 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: soared 3614.35% in 2022, then plummeted 97.87% in 2023.
  • Bio-Rad Laboratories' Liabilities and Shareholders Equity stood at $363.5 million in 2021, then skyrocketed by 3614.35% to $13.5 billion in 2022, then tumbled by 97.87% to $287.1 million in 2023, then surged by 3161.62% to $9.4 billion in 2024, then rose by 12.95% to $10.6 billion in 2025.
  • Per Business Quant, the three most recent readings for BIO's Liabilities and Shareholders Equity are $10.6 billion (Q4 2025), $9.7 billion (Q3 2025), and $10.2 billion (Q2 2025).